Thanks, Wayne. Consolidated total revenue for the fourth quarter of 2022 was $409.3 million, an increase of 3.7%, compared to $394.8 million in the prior year period. The increase was driven by our Infrastructure segment, led by Banker Steel and an increase in the Infrastructure market demand. Net loss attributable to common and participating preferred stockholders for the fourth quarter of 2022 was $7 million or $0.09 per share, compared to a net loss of $5.2 million or $0.07 per share in the prior year period. Total adjusted EBITDA, which excludes discontinued operations was $28.1 million in the fourth quarter of 2022, an increase from an adjusted EBITDA of $22.1 million in the prior year period. The increase was primarily driven by the Infrastructure segment, Life Sciences, Spectrum and non-operating corporate segments. This was partially offset by a decrease in equity method income from our investment in HMN, which as previously discussed, the sales of the remaining 19% closed in March of 2023. At Infrastructure, revenue increased 3.6% to $397.3 million from $383.4 million in the prior year quarter. As discussed earlier, this increase is driven by Banker Steel as they are in full swing into work at 270 Park. We also saw an increase in DBM’s commercial structural steel fabrication and erection business as they work through some of the larger wins from 2021 including IBEC Clippers’ arena and larger wins from 2022, including Stellantis, which is a lithium-ion battery production plant in Kokomo, Indiana. The increase was offset in part by the industrial maintenance and repair, construction, modeling and detailed businesses. Infrastructure adjusted EBITDA for the fourth quarter of 2022 increased to $32.7 million from $28.8 million in the prior year period. The increase was largely driven by improvement in margin at the commercial structural steel fabrication and erection, industrial maintenance and repair and construction modeling and detail businesses, as project sold in the first half of 2021 and earlier are working their way through the system and projects subsequently sold in the second half of 2021 are now beginning to ramp up. Additionally, contributing to the increase is a decrease in G&A expenses, which was partially offset by a decrease in the contribution from Banker Steel. While we experienced strong margin improvement in the fourth quarter our expectations for adjusted EBITDA margin for the full year 2023 will be a slight improvement to what was delivered in the full year of 2022. As of December 2022 reported backlog was $1.8 billion, up from $1.6 billion as of December 31, 2021. Adjusted backlog which takes into consideration awarded, but not yet signed contracts was $1.8 billion, compared to $1.9 billion at the end of December 2021. Team at DBMG continues to see a robust pipe line in 2023. DBMG ended the quarter with $243 million of debt, which is an increase of $54.4 million from year end 2021, driven by working capital movements resulting from topline business growth. At Life Sciences, the decrease in adjusted EBITDA losses was primarily driven by a decrease in equity method losses recorded from our investment in MediBeacon. Pansend’s net carrying amount of its investment in MediBeacon was reduced to zero in the current year, as losses incurred exceeded Pansend’s net basis in MediBeacon, resulting in fewer losses recognized than in the comparable period. However, as discussed above, we are encouraged by the progress of MediBeacon with the company completing enrollment in both the U.S. and China pivotal studies. At Spectrum, revenue remained consistent year-over-year at $10.7 million. Offsetting drivers included a decrease in advertising revenue at the Azteca network driven by decreased footprint and declines in paid programming and an offsetting increase in station revenues as they launched new customers and grew the number of its operating stations. Spectrum delivered adjusted EBITDA of $2.5 million in the fourth quarter, compared to adjusted EBITDA of $1.6 million in the prior quarter. The increase was driven by higher station revenues and a decrease in professional fees, legal expenses and salary and benefit expenses. This is partially offset by higher station costs as a result of the newly built stations. As previously disclosed in an 8-K filed with the SEC, during the fourth quarter of 2022, our seg -- our Spectrum segment entered an amendment to extend its senior secured notes to May 31, 2024. The interest rate of the 10.5% notes was increased to 11.45% and the accrued interest and fees of the $17.5 million were capitalized into the principal balance. The terms of the 8.5% notes remain the same. Total outstanding principal after the refinancing was $69.7 million. As part of the consideration for extending the 10.5% senior secured notes, our Spectrum segment amended the warrants held by the lenders of the notes by extending the time to exercise the second half of 2026 and reducing the exercise price per share to a penny. Non-operating corporate adjusted EBITDA losses were $3.7 million for the fourth quarter of 2022, down from the fourth quarter of 2021 by $800,000, driven mostly by a decrease in bonus expense, which was partially offset by an increase in professional fees. At the end of the fourth quarter, the company had $80.4 million of cash and cash equivalents, compared to $45.5 million as of December 31, 2021. On a standalone basis, as of December 31, 2022, the corporate segment had cash and cash equivalents of $9.1 million, compared to $22 million at the end of 2021. As Wayne mentioned, we recently closed the sale of the remaining 90% interest in HMN. The 19% HMN stake was held by Global Marine Holdings, LLC, and ending [ph] which INNOVATE holds approximately 73% controlling interest. The sale was consummated pursuant to the terms of a supplemental agreement entered into by the parties in June of 2022. After taxes and transaction fees, INNOVATE received approximately $32 million in cash, which would be used for reinvestment, debt repayment, specifically the $15 million of the outstanding credit line and general working capital. As of December 31, 2022, INNOVATE had total principal outstanding indebtedness of $725.3 million, up $94.5 million from $630.8 million at the end of 2021, driven primarily by Infrastructure’s increase in its credit line as a result of working capital movements, Spectrum’s refinancing, corporate’s utilization of the remaining credit line in the third quarter and R2’s borrowing from Lancer Capital. We are proud of the topline growth INNOVATE achieved in 2022 and with the progress made across all three of our business segments. Infrastructure continues to deliver reliable results with visibility into the runway for future growth in 2023 and beyond. Pansend’s R2 revenue is also trending in the right direction as it continues to benefit from the sale of its Glacial products, while MediBeacon is on track to submit their FDA trial this year. As we are seeing Spectrum’s profitability improved immediately as a result of the recent operational changes made to the business, as we continue to explore expanding the value of Spectrum through the benefits of next-gen technology. We look to build upon the results in 2022 and are well-positioned to continue our strong momentum in 2023. With that, Operator, we’d now like to open up the call for questions.